ERBB2 and breast carcinoma: PI3K inhibitor (BEZ235, AEW541), mTOR inhibitor (RAD001), and EGFR/HER2 inhibitor (lapatinib) suppress proliferation of letrozole-resistant breast cancer cells [9].